BBH

A broad and diverse effort is underway by biotech companies to solve the terrible riddle of the Coronavirus.Firms are forging ahead with testing, treatment and vaccine research and product development.Results of even the most promising treatments, however, are not yet clear cut. Even those that may be are not proof a bullish thesis for those companies that have developed them.Biotech investing is risky. The temptations of building a large position in a COVID 19-engaged public company are obvious.A wise investor would be well-served by opening or adding to such positions with a measure of caution.

Gold’s slump this week is forcing investors to ask whether the haven asset is taking a breather or facing an even sharper decline.

Five years ago, State Street started a new, green fund. The world hasn’t been the same since.

The case for the European Central Bank to add monetary stimulus gained momentum on Tuesday, with Executive Board Member Fabio Panetta saying policy makers should err on the side of doing more to keep the rebound on track.

More than two weeks of doubt and volatility in the stock market are finally starting to show up in corporate bonds.

The tech-led selloff in U.S. equities is likely only halfway done, according to the Morgan Stanley strategist whose warning last month about the top-heavy market now appears prescient.